Immunic
Market cap $116M 15.9M shares (10-Q, Nov 6, 2026) × $7.33 close Nov 17, 2026
Most recent annual filing: 2026-02-26
- vidofludimus calcium readout2026vidofludimus calcium readout, 2026, notable
- vidofludimus calcium PPMS Ph3 start2H 2026vidofludimus calcium PPMS Ph3 start, 2H 2026, routine
- vidofludimus calcium Ph3 toplineDec 2026vidofludimus calcium Ph3 topline, Dec 2026, thesis-defining
- ENSURE-1/ENSURE-2 toplineDec 2026ENSURE-1/ENSURE-2 topline, Dec 2026, material
- PROTECT-MS trial start1H 2027PROTECT-MS trial start, 1H 2027, routine
- vidofludimus calcium RMS NDA filingMid-2027vidofludimus calcium RMS NDA filing, Mid-2027, material
- vidofludimus calcium RMS FDA approval2028vidofludimus calcium RMS FDA approval, 2028, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
IMU-856
IMU-381
- Undisclosed indication
Technology platforms
Nurr1 platform
Nuclear receptor-related 1 (Nurr1) activation platform comprising next-generation small molecule derivatives (IMU-381 series) targeting neurologic, gastrointestinal, and autoimmune diseases
Targets: Nurr1
Capital (as filed)
- Cash
- $132M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$28.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $132M cash, runway late 2027 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-14 UPDATE: Immunic (IMUX) - Back Below the Smart-Money Line 🔒 Paid
- 2026-08-12 UPDATE: Immunic (IMUX) - The Founder Is Gone and the Auditors Priced a Sale at 50/50 🔒 Paid
- 2026-05-28 Immunic, Inc. (IMUX) — Scientific Deep Dive for Vidofludimus Calcium (IMU-838) and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Immunic, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-28 Watch Immunic, Inc. (IMUX) — Scientific Deep Dive for Vidofludimus Calcium (IMU-838) and Pipeline Products Strong smart-money signal and a credible binary catalyst inside 12 months are offset by a Phase 2 PMS primary miss, generic Aubagio as the pricing floor, fenebrutinib positive Phase 3 in both indications, and a heavy warrant and royalty stack; wait for ENSURE readouts before committing capital.
- 2026-08-12 Watch UPDATE: Immunic (IMUX) - The Founder Is Gone and the Auditors Priced a Sale at 50/50 Watch list maintained as the setup is clearer — runway confirmed, commercial bench complete, founder transition finished — but the stock at $15.48 is 77% above the smart-money PIPE mark, compressing the original asymmetry, while fenebrutinib, generic Aubagio, and the royalty stack remain unchanged.
- 2026-11-14 Speculative buy speculative UPDATE: Immunic (IMUX) - Back Below the Smart-Money Line Stock has fallen below the $8.73 smart-money PIPE mark weeks before the December ENSURE readout, restoring the original accumulate-below-$8.73 logic; the primary endpoint is meaningfully de-risked by EMPhASIS Phase 2 data, but any position should be sized for a total loss on a miss.
- Long call · opened Nov 16, 2026 at $7.23 · +1.4% vs XBI -0.4% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The top-line data for both ENSURE trials is expected in December 2026.”
matched to vidofludimus calcium (IMU-838) · topline data
-
-
-
“If positive, Immunic plans to submit a New Drug Application (NDA) in the United States in mid-2027, with a targeted potential regulatory approval date in 2028. · Vidofludimus Calcium in Progressive MS: The planned initiation of a Phase 3 program in progressive MS remains on track for later this year. · IMU-381: The IMU-381 program, selected to leverage the Nurr1 platform for neurologic and autoimmune diseases, continues to be in preclinical testing with lead candidate identification ongoing.”
matched to vidofludimus calcium (IMU-838) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (36)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 2026ReleaseImmunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 13, 20268-KCurrent report: results of operations · EX-99.1→ BD updateWith ENSURE top-line data now pinned to December 2026, IMUX has re-priced to $7.52 — below the $8.73 smart-money PIPE mark — while Q3 cash came in at $132M and the 50% corporate-transaction probability holds. Six weeks to the binary.
- Nov 13, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Nov 2, 2026ReleaseImmunic to Participate in Investor Conferences in November
- Oct 29, 2026ReleaseImmunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
- Oct 21, 2026ReleaseImmunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingBD extracted 1 program update from this document → IMUX pipeline
- Oct 19, 2026ReleaseImmunic Appoints Jaa Roberson as Chief People Officer
- Oct 7, 2026ReleaseImmunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingBD extracted 1 program update from this document → IMUX pipeline
- Sep 11, 20268-KCurrent report: officer / director change
- Sep 9, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Sep 2, 2026ReleaseImmunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
- Sep 1, 2026ReleaseImmunic Appoints Chitrang Davé as Chief Data and Digital Officer
- Aug 11, 2026ReleaseImmunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateBD extracted 1 program update from this document → IMUX pipeline
- Aug 11, 20268-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1
- Aug 11, 202610-QQuarterly report
- Aug 10, 2026ReleaseImmunic Appoints Elena Ridloff to Board of Directors
- Jul 14, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Jul 6, 20268-KCurrent report: officer / director change
- Jun 29, 20268-KCurrent report: officer / director change, shareholder vote
- May 29, 2026DEF 14AProxy statement
- May 28, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- May 27, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- May 19, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- May 13, 20268-KCurrent report: results of operations · EX-99.1
- May 13, 202610-QQuarterly report
- Apr 30, 2026S-3/AShelf registration (amended)
- Apr 28, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Apr 23, 20268-KCurrent report: holder rights modified, charter / bylaws / fiscal year, other events · EX-99.1
- Apr 22, 202610-K/AAnnual report (amended)
- Apr 14, 20268-KCurrent report: shareholder vote, other events
- Apr 10, 20268-KCurrent report: officer / director change
- Apr 2, 2026S-3Shelf registration
- Apr 1, 20268-KCurrent report: other events · EX-99.1
- Mar 31, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Mar 2, 2026DEF 14AProxy statement
23 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 13, 2026SCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- Nov 2, 2026SCHEDULE 13G/A13G amendment
- Oct 1, 2026S-8Employee plan registration
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Aug 12, 2026S-8Employee plan registration
- Aug 6, 2026SCHEDULE 13G/A13G amendment
- Aug 4, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 16, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 4, 2026EFFECTRegistration effective
- May 1, 2026CORRESPCORRESP
- Apr 17, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 9, 2026S-8Employee plan registration
- Apr 6, 2026UPLOADUPLOAD
- Mar 4, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 4, 2026DForm D (exempt offering)